MedPath

Pradaxa

These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively. See full prescribing information for PRADAXA Capsules. PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010

Approved
Approval ID

1a214cf1-b41e-46f6-8f24-e3637e6d2612

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 19, 2022

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dabigatran etexilate mesylate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63629-8242
Application NumberNDA022512
Product Classification
M
Marketing Category
C73594
G
Generic Name
dabigatran etexilate mesylate
Product Specifications
Route of AdministrationORAL
Effective DateJune 25, 2021
FDA Product Classification

INGREDIENTS (1)

DABIGATRAN ETEXILATE MESYLATEActive
Quantity: 150 mg in 1 1
Code: SC7NUW5IIT
Classification: ACTIR

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Pradaxa - FDA Drug Approval Details